LAMPA
Chemical compound
From Wikipedia, the free encyclopedia
Lysergic acid methylpropylamide (LAMPA, LAMP, or LMP), also known as LMP-55 or as N-methyl-N-propyllysergamide (MPLA), is a structural analogue of lysergic acid diethylamide (LSD) that has been studied as a potential treatment for alcoholism.[1] In animal studies, LAMPA was found to be nearly equipotent to ECPLA and MIPLA for inducing a head-twitch response. LAMPA appears to be significantly less potent than LSD in humans, producing little to no noticeable effects at doses of 100 μg.[2] It shows reduced-efficacy partial agonism of the serotonin 5-HT2A receptor relative to LSD, which may be responsible for its equivocal hallucinogenic effects.[3] LAMPA is not an explicitly controlled substance in the United States,[4] but may be considered implicitly controlled as it is an isomer of LSD.[5][6] The drug is not a controlled substance in Canada as of 2025.[7]
| Clinical data | |
|---|---|
| Other names | Lysergic acid methylpropylamide; LMP; LAMP; LAMPA; LMP-55; LMP55; MPLA; N-Methyl-N-propyllysergamide; N,6-Dimethyl-N-propyl-9,10-didehydroergoline-8β-carboxamide |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H25N3O |
| Molar mass | 323.440 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- Substituted lysergamide
- Ethylcyclopropyllysergamide (ECPLA)
- Methylisopropyllysergamide (MIPLA)
- Ethylpropyllysergamide (EPLA)